Delivery Order SPE2DB22D1106-SPE2DB25FEKM7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,386.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $9,048.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on June 18, 2025, with completion scheduled for June 20, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $27,320.78. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $7,764.93 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) with a completion date of August 20, 2025. This competitive award, issued on August 19, 2025, carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $7,891.76 delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count) on June 20, 2025, with completion scheduled for June 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $16,991.63 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of September 15, 2025. The delivery order was issued on September 12, 2025, with performance to take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at $5,976.54 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $43,473.13 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60 count) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract supporting federal pharmaceutical procurement needs. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,785.70 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed price contract. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. This delivery order represents a non-competitive purchase executed under an existing contract vehicle and will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a contract ceiling value of $29,588.62. This firm fixed-price delivery order, which is expected to conclude by August 15, 2025, represents a competitively awarded, non-set-aside contract with performance directed to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award demonstrates the contractor's...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEKM7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,288.52 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on April 24, 2025, with an ultimate completion date of April 25, 2025. This competitive award, issued under firm fixed-price terms with no set-aside designation, represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract's place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply relationship with the Defense Logistics Agency, which includes a prime IDC valued at $999,999,999.00 running through December 2026. The IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. Otezla (apremilast) is an immunomodulatory medication used to treat conditions such as psoriasis and psoriatic arthritis, and its procurement through DLA reflects the agency's responsibility for maintaining pharmaceutical inventory across Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 4/24/25 |